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Abstract Promising research developments in both basic 
and applied sciences, such as genomics and participatory 
health care approaches, have generated widespread inter-
est in personalized medicine among almost all scientific 
areas and clinicians. The term personalized medicine is, 
however, frequently used without defining a clear theoret-
ical and methodological background. In addition, to date 
most personalized medicine approaches still lack convinc-
ing empirical evidence regarding their contribution and 
advantages in comparison to traditional models. Here, we 
propose that personalized medicine can only fulfill the 
promise of optimizing our health care system by an inter-
disciplinary and translational view that extends beyond 
traditional diagnostic and classification systems.
Personalized medicine refers to the identification of risk 
factors and tailoring of management and treatment to the 
individual characteristics of each patient (1-3). This con-
cept proposes to classify individuals into subpopulations 
that differ in disease etiology, development, and prognosis, 
susceptibility to a particular disease or their response to a 
specific treatment. Preventive or therapeutic interventions 
can subsequently be targeted to those who will benefit, to 
save costs for those who will not respond, and to decrease 
side effects for those who are likely to respond adversely. 
In addition, personalized medicine is also of utmost impor-
tance in other aspects of medicine, outside the scope of 
treatment. Based on genomic information, patients and 
families can for example obtain personalized information 
about the predicted disease development and optimize 
patient management. Also, they can learn about the risk of 
this disease occurring in further pregnancies and possibili-
ties to prevent this by means of preimplantation genetic 
diagnosis. The term personalized medicine has become 
tremendously popular since US President Barack Obama, 
as a senator in 2006, introduced the Genomics and Person-
alized Medicine Act to facilitate the introduction of person-
alized medicine. Promising research developments in both 
basic and applied sciences, such as genomics (1-4) and 
participatory health care approaches (5-8) further boosted 
the common interest in personalized medicine among al-
most all scientific areas and clinicians.
However, the term personalized medicine is frequently 
used without defining a clear theoretical and meth-
odological background. In addition, although con-
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ceptually attractive, to date most personalized medicine 
approaches still lack convincing empirical evidence re-
garding their contribution, and advantages in compari-
son to traditional models. Here, we propose that person-
alized medicine can only fulfill the promise of optimizing 
our health care system by an interdisciplinary, translational, 
and transdiagnostic view that extends beyond traditional 
diagnostic and classification systems. We anticipate the fol-
lowing challenges for these developments:
1. Since personalized medicine includes a broad interdis-
ciplinary research area (including both basic and applied 
approaches), there is a need to develop a translational 
research framework. Such integrated interdisciplinary 
frameworks of personalized medicine are currently lacking, 
particularly in the more applied, clinical sciences, including 
concepts such as participatory health care, patient involve-
ment, or patient-centeredness (1-3,5,6). Consequently, a 
coherent framework for science, care, and management 
has to be developed, in which tailored and individual 
based approaches are used beyond traditional diagnostics 
and classification methods.
2. Studies on the comparative effectiveness of personal-
ized medicine in comparison with more traditional models 
are still scarce in almost all disciplines (1-3,7,8). However, 
to become the promised translational and interdisciplinary 
revolution of our health care system, the additional con-
tribution and advantages of personalized medicine ap-
proaches (eg, tailored vs non-tailored approaches) have to 
be systematically investigated and proven.
3. Tailored approaches based on multidisciplinary cumu-
lative data (including genetic, biomedical, and behavioral 
measures) from experimental and observational databas-
es – proposed as a prerequisite for personalized medicine 
– are insufficiently available (1-3,7,8). Only these databases 
provide the size and flexibility needed to explore and con-
firm some of the relevant risk factors and subgrouping vari-
ables, which can help to individualize treatment decisions. 
In addition, the methodology of identifying relevant factors 
within these databases needs to be developed further.
To integrate these various approaches and to develop a 
common strategy for personalized medicine, the Radboud 
University Nijmegen Medical Centre has founded a Task 
Force with a broad research and clinical scope (including 
a range of methodological approaches, such as genom-
ics, molecular biology, proteomics, epidemiology, and 
medical internet technology, as well as a range of 
medical and social disciplines, including urology, gynecol-
ogy, neurology, and medical psychology). This interdisci-
plinary Task Force has the potential to develop an integra-
tive framework of personalized medicine, by focusing on 
the following concrete goals:
1. Developing interdisciplinary and translational research 
networks for researchers, to develop innovative strategies 
and health care approaches in the area of personalized 
medicine;
2. Developing risk-factor based models for personalized 
medicine approaches that are no longer defined within ex-
isting classification and diagnostic systems, but are tailored 
to individualized risk factors of patients;
3. Assembling databases of genetic, biomedical, and be-
havioral data in cohort studies for testing generic and dis-
ease specific personalized medicine models;
4. Developing innovative methodological approaches of 
testing specific personalized medicine models from a 
genomic, social, epidemiological, and/or statistical view;
5. Conducting interdisciplinary and translational research 
into personalized medicine with a broad range of biomedi-
cal, chemical, technological, and social sciences;
6. Evaluating the additional contribution and cost-effec-
tiveness of personalized medicine approaches (eg, tai-
lored vs non-tailored care, patient involvement);
7. Implementing broad strategies of personalized medi-
cine and participatory health care into regular clinical care 
(eg, personalized risk-factor based approaches of tailored 
care for various conditions).
Only when we are able to develop this integrated person-
alized medicine framework, personalized medicine can ful-
fill its promise of increased effectiveness, broad availabil-
ity of personalized care approaches, and a stronger focus 
on participatory health care. The final goal is to develop 
a well-defined translational research and health care strat-
egy that has benefits for each individual patient.
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